Quantbot Technologies LP Invests $29,000 in Health Catalyst, Inc. (NASDAQ:HCAT)

Quantbot Technologies LP purchased a new stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) during the 4th quarter, Holdings Channel.com reports. The fund purchased 4,131 shares of the company’s stock, valued at approximately $29,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Impax Asset Management Group plc grew its position in shares of Health Catalyst by 7.7% during the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock worth $19,442,000 after buying an additional 195,525 shares during the period. Geode Capital Management LLC boosted its stake in Health Catalyst by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock valued at $11,749,000 after acquiring an additional 66,896 shares during the last quarter. State Street Corp grew its holdings in Health Catalyst by 2.5% during the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after acquiring an additional 28,251 shares during the period. Portolan Capital Management LLC bought a new stake in shares of Health Catalyst during the 3rd quarter valued at $5,402,000. Finally, Point72 Asset Management L.P. lifted its stake in shares of Health Catalyst by 69.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock valued at $4,208,000 after purchasing an additional 211,805 shares during the period. Institutional investors and hedge funds own 85.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on HCAT shares. Canaccord Genuity Group cut their target price on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 21st. Piper Sandler cut their price target on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. Royal Bank of Canada decreased their price objective on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Thursday, February 27th. KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a report on Wednesday, January 8th. Finally, Wells Fargo & Company reduced their price target on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.27.

Insider Buying and Selling

In related news, insider Linda Llewelyn sold 6,441 shares of Health Catalyst stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $5.43, for a total transaction of $34,974.63. Following the completion of the sale, the insider now owns 85,819 shares of the company’s stock, valued at approximately $465,997.17. The trade was a 6.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Daniel Lesueur sold 16,902 shares of Health Catalyst stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the sale, the chief operating officer now directly owns 216,250 shares of the company’s stock, valued at approximately $977,450. The trade was a 7.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,530 shares of company stock worth $299,572. Insiders own 2.50% of the company’s stock.

Health Catalyst Stock Performance

HCAT opened at $4.33 on Wednesday. The business’s 50-day simple moving average is $4.98 and its 200 day simple moving average is $6.80. Health Catalyst, Inc. has a 52-week low of $3.76 and a 52-week high of $9.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The firm has a market capitalization of $304.01 million, a PE ratio of -3.21 and a beta of 1.41.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.